This funding supports collaborative research projects addressing chronic and delayed adverse sequelae of cancer therapies. It includes basic, translational, and clinical studies to identify mechanisms, clinically characterize outcomes, and develop therapeutic strategies. Projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to validate clinical endpoints for future clinical trials.
Eligible applicants include a wide range of U.S. organizations such as public and private institutions of higher education, nonprofits, tribal governments and organizations, local and state governments, small businesses, and for-profit organizations. Specific eligibility details are provided in the
